But pharmaceutical innovation isn't the same as complete solutions
When it comes to human trials, the data on DSIP is small, old, and mixed
Droxidopa (100-600 mg TID may be also tested, but is contraindicated in pregnancy) Effective in hypovolemic subtype of POTS and low blood pressure phenotype with pronounced orthostatic intolerance (Fedorowski 2018)
Its triple-action approachtargeting appetite, digestion, and energy expenditure at the same timehelps explain why the weight loss numbers are so striking
Effects of short-term exenatide treatment on regional fat distribution, glycated hemoglobin levels, and aortic pulse wave velocity of obese type 2 diabetes mellitus patients
Many people starting their journey with metabolic health find the transition from traditional oral medications to injectable peptides like tirzepatide to be a steep learning curve